<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Tempest Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/tempest-therapeutics-inc</link>
<description>Latest news and press releases for Tempest Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/tempest-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835cb9878dffbe2df11d397.webp</url>
<title>Tempest Therapeutics Inc</title>
<link>https://6ix.com/company/tempest-therapeutics-inc</link>
</image>
<item>
<title>Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting</title>
<link>https://6ix.com/company/tempest-therapeutics-inc/news/tempest-to-advance-dual-targeting-car-t-platform-with-clinical-update-at-isct-2026-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/tempest-therapeutics-inc/news/tempest-to-advance-dual-targeting-car-t-platform-with-clinical-update-at-isct-2026-annual-meeting</guid>
<pubDate>Wed, 29 Apr 2026 12:00:00 GMT</pubDate>
<description>Presentation will showcase recent data from multiple clinical studies evaluating dual-targeting CD19/BCMA CAR-T therapy candidate TPST-2003Results support clinical benefit of parallel-structure dual-targeting CAR architecture in patients with relapsed/refractory multiple myelomaData further support potential of TPST-2003 to improve outcomes for patients with extramedullary disease BRISBANE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”) will pres</description>
</item>
<item>
<title>Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T</title>
<link>https://6ix.com/company/tempest-therapeutics-inc/news/tempest-announces-key-manufacturing-milestone-for-tpst-2003-dual-targeting-cd19bcma-car-t-2</link>
<guid isPermaLink="true">https://6ix.com/company/tempest-therapeutics-inc/news/tempest-announces-key-manufacturing-milestone-for-tpst-2003-dual-targeting-cd19bcma-car-t-2</guid>
<pubDate>Wed, 22 Apr 2026 04:00:00 GMT</pubDate>
<description>Delivery of TPST-2003 lentiviral vector to Cincinnati Children’s Applied Gene and Cell Therapy Center enables manufacturing activities required for pivotal</description>
</item>
<item>
<title>Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts</title>
<link>https://6ix.com/company/tempest-therapeutics-inc/news/tempest-appoints-andrew-fang-phd-as-head-of-business-development-to-advance-strategic-partnerships-and-global-licensing-efforts</link>
<guid isPermaLink="true">https://6ix.com/company/tempest-therapeutics-inc/news/tempest-appoints-andrew-fang-phd-as-head-of-business-development-to-advance-strategic-partnerships-and-global-licensing-efforts</guid>
<pubDate>Tue, 14 Apr 2026 04:00:00 GMT</pubDate>
<description>Adds dedicated business development leadership to support Tempest’s strategic prioritiesWill lead China outreach and cross-border partnership effortsTo</description>
</item>
<item>
<title>Tempest Reports Year End 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/tempest-therapeutics-inc/news/tempest-reports-year-end-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/tempest-therapeutics-inc/news/tempest-reports-year-end-2025-financial-results-and-provides-business-update</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>Completed strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc. Named Matt Angel, Ph.D., Chief Executive Officer & President</description>
</item>
<item>
<title>Tempest Therapeutics Announces Up To $6 Million Private Placement</title>
<link>https://6ix.com/company/tempest-therapeutics-inc/news/tempest-therapeutics-announces-up-to-dollar6-million-private-placement</link>
<guid isPermaLink="true">https://6ix.com/company/tempest-therapeutics-inc/news/tempest-therapeutics-announces-up-to-dollar6-million-private-placement</guid>
<pubDate>Mon, 23 Mar 2026 12:00:00 GMT</pubDate>
<description>$2 million upfront with up to approximately $4 million of potential aggregate gross proceeds upon the exercise in full of warrantsBRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (the “Company”), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 925,927 shares of comm</description>
</item>
<item>
<title>Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026</title>
<link>https://6ix.com/company/tempest-therapeutics-inc/news/tempest-announces-partnership-for-tpst-2003-in-preparation-for-planned-us-registrational-study-in-2026</link>
<guid isPermaLink="true">https://6ix.com/company/tempest-therapeutics-inc/news/tempest-announces-partnership-for-tpst-2003-in-preparation-for-planned-us-registrational-study-in-2026</guid>
<pubDate>Wed, 11 Mar 2026 04:00:00 GMT</pubDate>
<description>Cincinnati Children’s Applied Gene and Cell Therapy Center selected to conduct tech transfer, development and IND-enabling manufacturingAll activities other</description>
</item>
<item>
<title>Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026</title>
<link>https://6ix.com/company/tempest-therapeutics-inc/news/tempest-announces-interim-results-from-ongoing-redeem-1-trial-of-tpst-2003-preparing-for-potential-us-registrational-study-in-2026</link>
<guid isPermaLink="true">https://6ix.com/company/tempest-therapeutics-inc/news/tempest-announces-interim-results-from-ongoing-redeem-1-trial-of-tpst-2003-preparing-for-potential-us-registrational-study-in-2026</guid>
<pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
<description>100% complete response (CR) rate among all six efficacy evaluable patientsFavorable safety profile with no Grade >3 CRS or ICANSPrior investigator-initiated</description>
</item>
<item>
<title>Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets</title>
<link>https://6ix.com/company/tempest-therapeutics-inc/news/tempest-lays-strategic-plan-advance-115900017</link>
<guid isPermaLink="true">https://6ix.com/company/tempest-therapeutics-inc/news/tempest-lays-strategic-plan-advance-115900017</guid>
<pubDate>Wed, 11 Feb 2026 11:59:00 GMT</pubDate>
<description>Tempest outlines a capital-efficient post-transaction strategy to advance a diversified portfolio of next-generation CAR-T and oncology assetsDevelopment approach prioritizes partner-funded and externally supported programs to generate clinical data before deploying significant internal capitalPipeline expansion includes TPST-4003, an in vivo dual-targeting CD19/BCMA CAR-T, with potential near-term milestones BRISBANE, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq:</description>
</item>
<item>
<title>Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets</title>
<link>https://6ix.com/company/tempest-therapeutics-inc/news/tempest-announces-closing-strategic-acquisition-214700394</link>
<guid isPermaLink="true">https://6ix.com/company/tempest-therapeutics-inc/news/tempest-announces-closing-strategic-acquisition-214700394</guid>
<pubDate>Wed, 04 Feb 2026 21:47:00 GMT</pubDate>
<description>All-stock transaction brings Tempest a portfolio of next-generation CAR-T assets, including TPST-2003, a clinical-stage dual-targeting CD-19/BCMA CAR-T with strategic partner-funded BLA filing in China planned for 2027Operational runway extended to mid-2027, supporting multiple potential value-generating milestonesMatt Angel, Ph.D., joins Tempest as President and CEOPreviously announced transaction closed following stockholder approval of share issuance at the 2025 Annual Meeting on January 27,</description>
</item>
<item>
<title>Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders</title>
<link>https://6ix.com/company/tempest-therapeutics-inc/news/tempest-announces-record-date-anticipated-222000278</link>
<guid isPermaLink="true">https://6ix.com/company/tempest-therapeutics-inc/news/tempest-announces-record-date-anticipated-222000278</guid>
<pubDate>Tue, 20 Jan 2026 22:20:00 GMT</pubDate>
<description>BRISBANE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company with a pipeline of targeted and immune-mediated therapeutics to fight cancer, today announced the record date of January 30, 2026 (the “Record Date”) for the distribution of warrants to purchase Tempest common stock (“Warrants”) as a dividend (the “Warrant Dividends”), as contemplated by Tempest’s previously announced Asset Purchase Agreement (the “Ass</description>
</item>
<item>
<title>Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/tempest-therapeutics-inc/news/tempest-announces-closing-8-35-210500528</link>
<guid isPermaLink="true">https://6ix.com/company/tempest-therapeutics-inc/news/tempest-announces-closing-8-35-210500528</guid>
<pubDate>Wed, 26 Nov 2025 21:05:00 GMT</pubDate>
<description>$4.25 million upfront with up to an additional $4.1 million of potential aggregate gross proceeds upon the exercise in full of short-term unregistered warrantsBRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced the closing of its previously announced registered direct offering priced at the market under Nas</description>
</item>
<item>
<title>Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/tempest-therapeutics-inc/news/tempest-announces-8-35-million-130000953</link>
<guid isPermaLink="true">https://6ix.com/company/tempest-therapeutics-inc/news/tempest-announces-8-35-million-130000953</guid>
<pubDate>Tue, 25 Nov 2025 13:00:00 GMT</pubDate>
<description>$4.25 million upfront with up to an additional $4.1 million of potential aggregate gross proceeds upon the exercise in full of short-term unregistered warrantsBRISBANE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional in</description>
</item>
<item>
<title>Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027</title>
<link>https://6ix.com/company/tempest-therapeutics-inc/news/tempest-announces-strategic-acquisition-dual-140000283</link>
<guid isPermaLink="true">https://6ix.com/company/tempest-therapeutics-inc/news/tempest-announces-strategic-acquisition-dual-140000283</guid>
<pubDate>Wed, 19 Nov 2025 14:00:00 GMT</pubDate>
<description>All-stock acquisition includes clinical-stage CD19/BCMA Dual-CAR T programAcquisition will expand existing advanced clinical-stage pipeline of amezalpat (PPAR⍺ Antagonist, Phase 3-ready) and TPST-1495 (Dual Ep2/4 Antagonist, Phase 2 start expected near term)The anticipated preclosing equity financing and an investment commitment from Factor Bioscience is expected to extend Tempest’s runway to mid 2027 and through potentially significant milestonesPlan to proceed with execution of globally approv</description>
</item>
<item>
<title>Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/tempest-therapeutics-inc/news/tempest-reports-third-quarter-2025-133000535</link>
<guid isPermaLink="true">https://6ix.com/company/tempest-therapeutics-inc/news/tempest-reports-third-quarter-2025-133000535</guid>
<pubDate>Wed, 05 Nov 2025 13:30:00 GMT</pubDate>
<description>BRISBANE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended September 30, 2025 and provided a corporate update. “We are continuing our strategic alternatives process with the goal of maximizing value for stockholders,” said Stephen Brady, president and chief executive officer</description>
</item>
<item>
<title>Vividion Therapeutics Appoints Sam Whiting, M.D., Ph.D., as Chief Medical Officer</title>
<link>https://6ix.com/company/tempest-therapeutics-inc/news/vividion-therapeutics-appoints-sam-whiting-md-phd-as-chief-medical-officer-1</link>
<guid isPermaLink="true">https://6ix.com/company/tempest-therapeutics-inc/news/vividion-therapeutics-appoints-sam-whiting-md-phd-as-chief-medical-officer-1</guid>
<pubDate>Wed, 13 Aug 2025 12:00:00 GMT</pubDate>
<description>SAN DIEGO, August 13, 2025--Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, today announced the appointment of Sam Whiting, M.D., Ph.D., as Chief Medical Officer. Dr. Whiting is an accomplished medical oncologist who brings to Vividion more than two decades of experience spanning patient care, early drug discovery, and late-stage global clinical development. Vividion utilizes innovative disc</description>
</item>
<item>
<title>Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/tempest-therapeutics-inc/news/tempest-reports-second-quarter-2025-201200834</link>
<guid isPermaLink="true">https://6ix.com/company/tempest-therapeutics-inc/news/tempest-reports-second-quarter-2025-201200834</guid>
<pubDate>Mon, 11 Aug 2025 20:12:00 GMT</pubDate>
<description>Received clearance to proceed with pivotal trial of amezalpat combination therapy for first-line hepatocellular carcinoma (HCC) in ChinaGranted orphan drug designation from the European Medicines Agency (EMA) for amezalpat for the treatment of patients with HCCPresented new amezalpat mechanism-of-action data reinforcing its potential as a novel cancer treatment at the 2025 AACR Annual MeetingGranted Orphan Drug designation by FDA for TPST-1495 for the treatment of familial adenomatous polyposis</description>
</item>
<item>
<title>Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China</title>
<link>https://6ix.com/company/tempest-therapeutics-inc/news/tempest-receives-clearance-proceed-pivotal-120000678</link>
<guid isPermaLink="true">https://6ix.com/company/tempest-therapeutics-inc/news/tempest-receives-clearance-proceed-pivotal-120000678</guid>
<pubDate>Mon, 30 Jun 2025 12:00:00 GMT</pubDate>
<description>Builds on clearances already received by FDA and EMAChina has the largest population of patients with hepatocellular carcinoma in the world BRISBANE, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that the company received approval from the National Medical Products Administration (NMPA) in China to proceed with</description>
</item>
<item>
<title>Tempest Announces $4.6 Million Registered Direct Offering of Common Stock</title>
<link>https://6ix.com/company/tempest-therapeutics-inc/news/tempest-announces-4-6-million-120000320</link>
<guid isPermaLink="true">https://6ix.com/company/tempest-therapeutics-inc/news/tempest-announces-4-6-million-120000320</guid>
<pubDate>Wed, 11 Jun 2025 12:00:00 GMT</pubDate>
<description>BRISBANE, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale in a registered direct offering of 739,000 shares of its common stock (or common stock equivalents), at an offering price of $6.25 per share of c</description>
</item>
<item>
<title>Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC</title>
<link>https://6ix.com/company/tempest-therapeutics-inc/news/tempest-receives-orphan-drug-designation-120000996</link>
<guid isPermaLink="true">https://6ix.com/company/tempest-therapeutics-inc/news/tempest-receives-orphan-drug-designation-120000996</guid>
<pubDate>Thu, 05 Jun 2025 12:00:00 GMT</pubDate>
<description>EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, underscoring the urgent need for new treatment optionsThe multiple regulatory designations were granted following strong positive results from a global randomized Phase 1b/2 study in first-line HCC demonstrating superior outcomes for amezalpat combination therapy across multiple study endpoints, including overall survival in both the entire population and key subpopulations, when com</description>
</item>
<item>
<title>Tempest Reports First Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/tempest-therapeutics-inc/news/tempest-reports-first-quarter-2025-202800626</link>
<guid isPermaLink="true">https://6ix.com/company/tempest-therapeutics-inc/news/tempest-reports-first-quarter-2025-202800626</guid>
<pubDate>Tue, 13 May 2025 20:28:00 GMT</pubDate>
<description>Presented new amezalpat mechanism-of-action data reinforcing its potential as a novel cancer treatment at the 2025 AACR Annual MeetingGranted Orphan Drug designation by FDA for TPST-1495 for the treatment of familial adenomatous polyposis (FAP)Received FDA “Study May Proceed” letter for Phase 2 trial of TPST-1495 for the treatment of FAPGranted both Orphan Drug & Fast Track designations by FDA for Amezalpat (TPST-1120) for the treatment of patients with hepatocellular carcinoma (HCC) BRISBANE, C</description>
</item>
</channel>
</rss>